Latest
Solar3D up-lists to NASDAQ on strength of acquisitions
The firm raked in $20.2 million in revenue for 2014 and reported operating income of $311,072, compared to an operating loss of $1.1 million for the same period in 2013.
Latest
Amgen’s portfolio threatened as FDA paves path for lower-cost drugs
Zarxio, the first biopharmaceutical copycat approved in the U.S., will pave the way for lower-cost alternatives to existing treatments.
